Radiobiology

THERYQ and Gustave Roussy have been selected as part of the "i-Démo" France 2030 call for projects, operated on behalf of the French government by Bpifrance, for the "FLASHDEEP" project, for an amount of 38 million euros

Retrieved on: 
Friday, February 2, 2024
CERN, Radiation therapy, Neoplasm, Research, Teaching hospital, DGE, Gustave Roussy, CHUV, Patient, FLASH, Radiation, Physician, Electron, Cancer, CE, Radiobiology, Pharmaceutical industry

FLASHDEEP will be the world's first FLASH radiotherapy device using very high-energy electrons (VHEE; > 100 MeV).

Key Points: 
  • FLASHDEEP will be the world's first FLASH radiotherapy device using very high-energy electrons (VHEE; > 100 MeV).
  • The particle acceleration technology developed by THERYQ stems from research initiated by the European Organization for Nuclear Research (CERN) and the University Hospital of Lausanne (CHUV).
  • The first clinical FLASHDEEP device will be installed in France, at Gustave Roussy, late 2026, to conduct clinical trials with eligible patients.
  • Ultimately, it will lead to the revival of a French radiotherapy industrial sector, a field that has been neglected since the late 1980s.

AdvanCell Appoints Anna Karmann, MD, PhD as Chief Medical Officer

Retrieved on: 
Thursday, January 4, 2024
Research, Biotechnology, Other Health, Radiology, Health, Pharmaceutical, Other Science, Science, Oncology, Molecular imaging, McKinsey & Company, IND, Drug development, Maastricht University, RWTH Aachen University, MBA, Alpha, MD, Doctor of Philosophy, Tsinghua University, Cancer, Investigational New Drug, Stanford University Medical Center, CA9, Patient, Radiopharmaceutical, Bristol Myers Squibb, Therapy, GPC3, Radiobiology

AdvanCell, a clinical-stage radiopharmaceutical company developing a pipeline of Targeted Alpha Therapies for patients with cancer, today announced the appointment of Anna Karmann, MD, PhD as the company’s Chief Medical Officer based in San Francisco.

Key Points: 
  • AdvanCell, a clinical-stage radiopharmaceutical company developing a pipeline of Targeted Alpha Therapies for patients with cancer, today announced the appointment of Anna Karmann, MD, PhD as the company’s Chief Medical Officer based in San Francisco.
  • Anna has over 15 years of experience in the biopharma industry, drug development, and clinical practice.
  • Anna holds an MD from RWTH Aachen University, a PhD from Maastricht University, and an MBA from RWTH Aachen University and Tsinghua University Beijing.
  • She gained significant clinical practice and clinical research experience at the University Medical Center Maastricht, Netherlands and Stanford University Hospital, CA, USA.

Centre for Ion Beam Applications at NUS designated as IAEA's first Collaborating Centre in Singapore

Retrieved on: 
Wednesday, September 20, 2023
Faculty, DNA, Nanoparticle, Collaborating Centre for Oxford University and CUHK for Disaster and Medical Humanitarian Response, Singapore Synchrotron Light Source, United Nations, Partnership, CIBA, Durham University Department of Physics, National University of Singapore, Ion Beam Applications, National university, Biomedical Research, Light, Research, Multimedia, Microprobe, Development, Student, Acceleration, IAEA, DNA repair, CRP, Agency, International Atomic Energy Agency, Nanofluidic circuitry, Radiobiology, Nucleus, Knowledge, Diagnosis, Chronic radiation syndrome, NUS Faculty of Law, NUS, McMaster Faculty of Science, Tutoring, Uranium mining, Rare-earth element, Medical imaging, Pharmaceutical industry, Science, Physics

SINGAPORE, Sept. 20, 2023 /PRNewswire/ -- The Centre for Ion Beam Applications (CIBA), a multidisciplinary research centre at the National University of Singapore (NUS), has recently been designated as an International Atomic Energy Agency (IAEA) Collaborating Centre for Research and Development of Accelerator Science and Multidisciplinary Applications. A Memorandum of Understanding was signed by both parties on 13 September 2023 to formalise the four-year collaboration.

Key Points: 
  • SINGAPORE, Sept. 20, 2023 /PRNewswire/ -- The Centre for Ion Beam Applications (CIBA), a multidisciplinary research centre at the National University of Singapore (NUS), has recently been designated as an International Atomic Energy Agency (IAEA) Collaborating Centre for Research and Development of Accelerator Science and Multidisciplinary Applications.
  • "The designation of NUS CIBA as an IAEA Collaborating Centre is a testament to our researchers' quality innovations and expertise.
  • The IAEA Collaborating Centre will leverage CIBA's phenomenal research facilities to build capacity and transfer knowledge in Singapore, in Asia and beyond."
  • The Collaborating Centre will focus on four thematic areas:
    The Collaborating Centre will be developing ways to use ion beams to identify the elemental composition and structure of materials.

Xtalks Announces its Life Science Webinar Calendar for September 2023

Retrieved on: 
Friday, September 1, 2023
LAI, Food, Health care, Impact, Health, History, UAT, Biomarker, Development, Clinical trial, Universal language, Visibility, Data, Clinical study design, Drug discovery, Site, Physics, Research, Dynamic method, FDA, Integration, Success, Pharmaceutical industry, Medical device, Fine chemical, Birth control, Radiobiology, Xtalk

TORONTO, Sept. 1, 2023 /PRNewswire-PRWeb/ -- Stay on top of current hot topics through free webinars presented by leading experts in the pharma, biotech, medical device and food industries. Access to all webinars is free, so be sure to register today to save your place! Participate in the discussion and stay relevant in your field!

Key Points: 
  • Upcoming free, educational webinars from Xtalks will feature topics on biomarkers, clinical trials, commercialization & HEOR, drug discovery & development, food, healthcare, laboratory technology, medical device, patient recruitment & retention, pharmaceutical and pharma manufacturing & supply chain.
  • TORONTO, Sept. 1, 2023 /PRNewswire-PRWeb/ -- Stay on top of current hot topics through free webinars presented by leading experts in the pharma, biotech, medical device and food industries.
  • Access to all webinars is free, so be sure to register today to save your place!
  • Participate in the discussion and stay relevant in your field!

Delcath Systems Appoints Vojislav Vukovic as Chief Medical Officer

Retrieved on: 
Tuesday, June 20, 2023
Drug development, University, Senior, American Society of Clinical Oncology, Cancer, Radiobiology, American Association for Cancer Research, Oncology, CMO, University of Sarajevo, Doctor of Philosophy, European Society for Medical Oncology, MD, Patient, American Society of Hematology, Master of Science, Delcath Systems, Liver, Therapy, Society, Medical imaging, Nursing

NEW YORK, June 20, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Dr.  Vojislav "Vojo" Vukovic as its new Chief Medical Officer (CMO).

Key Points: 
  • NEW YORK, June 20, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Dr.  Vojislav "Vojo" Vukovic as its new Chief Medical Officer (CMO).
  • His experience spans early to late-stage oncology clinical projects and global medical affairs programs across multiple anti-cancer modalities and tumor types.
  • He has held the position of Senior Vice President and Chief Medical Officer at Aileron Therapeutics, Taiho Oncology Inc., and Synta Pharmaceuticals Inc. overseeing various facets of clinical development, medical affairs and corporate strategy.
  • "We are excited to welcome Dr. Vukovic to the executive leadership team," said Gerard Michel, CEO of Delcath Systems.

CNL Aims to Better Protect Canadian Astronauts Through New Project Funded by the Canadian Space Agency

Retrieved on: 
Tuesday, May 16, 2023
Science, technology, engineering, and mathematics, SPE, Canadian Nuclear Laboratories Research Facilities, Radiation, CNL, AECL, CSA, Canadian Space Agency, GCR, FNST, Applied physics, Spacecraft, Research, Neutron, Rolls-Royce SMR, STDP, NASA, Astronaut, Artemis, Radiobiology, News, Safety, National Research Council, Uranium mining, Science, Mars

In recent years, CNL has been conducting research on nanocomposite materials in radiation environments in collaboration with the National Research Council of Canada.

Key Points: 
  • In recent years, CNL has been conducting research on nanocomposite materials in radiation environments in collaboration with the National Research Council of Canada.
  • The STDP initiative aims to explore novel approaches to enhance the characteristics of such nanomaterials, making them suitable for space applications.
  • This growing momentum and interest in space exploration signals good news for CNL, who has seen its work increasingly being used to support research related to space travel.
  • For more information on CNL, including its work in materials sciences and radiobiology, please visit www.cnl.ca .

Perspective Therapeutics Announces the Awarding of a $1 million Collaborative Grant to King’s College London to Support Radiobiology Research of Alpha Particle Therapy for Cancer

Retrieved on: 
Wednesday, March 8, 2023
Therapy, Medical Research Council (United Kingdom), UK Research and Innovation, Neuroendocrine cell, Pancreas, CATX, Neoplasm, NYSE, Cancer, NETS, Senior lecturer, Isotope, Appendix, Radiation, Tissue, Cell, Medical Research Council, Patient, Associate, Auger, Rectum, Glomus tumor, MRC, Travel, Perspective, UKRI, United Kingdom, Radiobiology, Pharmaceutical industry, Medical imaging, IOWA, Research

RICHLAND, WASHINGTON & CORALVILLE, IOWA, March 08, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (formerly known as “Isoray, Inc.”) (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy powering expanding treatment options for multiple cancers, announced the awarding of a $1 million research grant from the Medical Research Council (MRC), part of UK Research and Innovation (UKRI) (www.ukri.org), to collaborator Samantha Terry PhD, Associate Professor (Senior Lecturer) at King’s College London.

Key Points: 
  • “My research is focused on the interactions of radiation with cells at a fundamental level.
  • Under the project, Perspective Therapeutics’ scientists will collaborate on radiobiology research, and provide isotopes and peptide precursors.
  • Perspective Therapeutics is supporting a graduate student working toward a doctorate in radiobiology under the guidance of Dr. Terry.
  • We are excited to be part of the research project and providing support for thought leading scientists in this area of research.”

Canadian Nuclear Laboratories and Jubilant Radiopharma to Collaborate on the Development of Novel Alpha Radiopharmaceuticals

Retrieved on: 
Friday, February 3, 2023
Nuclear medicine, Nuclear, Atomic energy, Waste management, National Nuclear Laboratory, CNL, Business development, CNRI, Jubilant, Actinium-225, Radiobiology, Radiopharmaceutical, Science and technology, Good laboratory practice, Center for Drug Evaluation and Research, SMR, Research, Atomic Energy of Canada Limited, Medical imaging, Pharmaceutical industry, Science, Health

CHALK RIVER, Ontario, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Canadian Nuclear Laboratories (CNL), Canada’s premier nuclear science and technology organization, is pleased to announce that it will collaborate with Jubilant Radiopharma, an international leader in radiopharmaceuticals, on the development of novel alpha radiopharmaceuticals.

Key Points: 
  • CHALK RIVER, Ontario, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Canadian Nuclear Laboratories (CNL), Canada’s premier nuclear science and technology organization, is pleased to announce that it will collaborate with Jubilant Radiopharma, an international leader in radiopharmaceuticals, on the development of novel alpha radiopharmaceuticals.
  • The new research cooperation with Jubilant represents the first project in the new CNRI-H program, which is designed to accelerate the development of targeted radiopharmaceuticals in Canada through joint research projects related to health sciences, radiobiology and medical isotope development.
  • “CNL launched CNRI-H to advance the development of targeted radiopharmaceuticals in Canada through collaborations with pioneering health sciences organizations.
  • “Canadian Nuclear Laboratories is uniquely equipped in this country to undertake research using these alpha-emitting isotopes,” commented George Baidoo, CNL’s Technical Director of Health in Business Development.

CNL’S Vision to Become a World Leader in Actinium-225 is Coming to Life

Retrieved on: 
Thursday, February 2, 2023
Nuclear medicine, Nuclear, Good laboratory practice, Atomic Energy of Canada Limited, Safety, International, Atomic energy, Cancer, Triangle Universities Nuclear Laboratory, CNL, ITM, Active ingredient, TAT, Isotope, Teva Active Pharmaceutical Ingredients, Actinium-225, Hope, API, Chalk River Laboratories, Radiobiology, Radiopharmaceutical, Alpha particle, Research, Fine chemical, Medical imaging

CHALK RIVER, Ontario, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Canadian Nuclear Laboratories (CNL), Canada’s premier nuclear science and technology laboratory, is celebrating a key milestone in its vision to become a world leader in the research and production of Actinium-225, a promising but very rare medical isotope. The end of 2022 marked five years since the first successful shipment of Actinium-225, and CNL has been shipping this product successfully and reliably ever since, which recently included its 100th shipment. Furthermore, CNL has realized steady progress during that same time, including establishing research-scale production facilities at the Chalk River Laboratories campus, implementing international standards to perform pre-clinical research at the site, and securing a global network of partners needed to eventually deliver a stable, commercial supply of the isotope.

Key Points: 
  • CNL is now working to position itself as a world leader and international hub for targeted alpha therapy (TAT) and for the production of the extremely rare and promising Actinium-225 isotope.
  • Both of these accomplishments position CNL to advance research related to TAT and Actinium-225 on its campus and using its own materials.
  • As Actinium-225 decays, it emits high-energy alpha particles that effectively kill cancer cells, leaving nearby healthy cells unharmed in the process.
  • To learn more about CNL, including its work in health sciences, please visit www.cnl.ca .

CNL, AECL and the University of Ottawa Sign MOU to Pursue Collaborative Research Opportunities

Retrieved on: 
Thursday, November 24, 2022
University, Graphite-moderated reactor, Heart, Atomic Energy of Canada Limited, Waste management, Environment, Organization, Isotope, Private sector, Chalk River Laboratories, Vision 2030, Partnership, MOU, Government, Radiation, Research, Science and technology, National Nuclear Laboratory, CANDU, Radiobiology, Cancer, Entrepreneurship, Health, Intellectual property, Crown, University of Ottawa, AECL, Safety, CNL, Renewable energy, Uranium, Management, Science

CHALK RIVER, Ontario, Nov. 24, 2022 (GLOBE NEWSWIRE) -- Canadian Nuclear Laboratories (CNL), Canada’s premier nuclear science and technology laboratory, is pleased to announce that it has signed a Memorandum of Understanding (MOU) with Atomic Energy of Canada Limited (AECL), Canada’s nuclear Crown Corporation, and the University of Ottawa to identify and pursue collaborative research opportunities. Building on decades of work together, the MOU formalizes what has been a longstanding relationship between the organizations in order to facilitate joint research projects, foster the professional development of highly qualified personnel, and encourage shared access to specialized infrastructure, all to advance research in health and environmental sciences, clean energy and nuclear safety.

Key Points: 
  • Alongside CNL, AECL is incredibly excited to enter into this agreement with the University of Ottawa, an organization who shares our passion for research, innovation and entrepreneurship, commented Amy Gottschling, Vice-President, Science, Technology & Commercial Oversight, AECL.
  • This objective is at the heart of this agreement with the University of Ottawa, and we are confident that our work will yield results that offer real, meaningful benefits for Canadians.
  • We share their determination to be agile and to seize every opportunity to continually push back the frontiers of research and development.
  • Today it delivers value for Canadians through supporting 14 federal departments and agencies, as well as the global nuclear industry.